Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Receivables - Accured (2023 - 2025)

Metagenomi (MGX) has disclosed Receivables - Accured for 3 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Accured fell 25.0% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 million, a 25.0% decrease, with the full-year FY2025 number at $1.2 million, down 25.0% from a year prior.
  • Receivables - Accured was $1.2 million for Q4 2025 at Metagenomi, down from $1.3 million in the prior quarter.
  • In the past five years, Receivables - Accured ranged from a high of $1.6 million in Q3 2024 to a low of $1.0 million in Q4 2023.
  • A 3-year average of $1.4 million and a median of $1.4 million in 2024 define the central range for Receivables - Accured.
  • Peak YoY movement for Receivables - Accured: skyrocketed 60.0% in 2024, then fell 25.0% in 2025.
  • Metagenomi's Receivables - Accured stood at $1.0 million in 2023, then soared by 60.0% to $1.6 million in 2024, then dropped by 25.0% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for MGX's Receivables - Accured are $1.2 million (Q4 2025), $1.3 million (Q3 2025), and $1.4 million (Q2 2025).